Greenleaf Trust Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Greenleaf Trust boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 22.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,209 shares of the medical device company's stock after acquiring an additional 3,114 shares during the quarter. Greenleaf Trust's holdings in DexCom were worth $1,175,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new position in shares of DexCom in the fourth quarter worth about $5,812,000. Golden State Wealth Management LLC increased its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Private Trust Co. NA raised its position in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after purchasing an additional 335 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of DexCom by 29.3% during the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after buying an additional 702 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC grew its position in shares of DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after buying an additional 1,333 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Piper Sandler reduced their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group increased their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Citigroup reiterated a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Truist Financial began coverage on DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price objective on the stock. Finally, Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price for the company. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Stock Up 0.7%

DXCM stock opened at $85.46 on Friday. The stock has a market cap of $33.51 billion, a PE ratio of 63.78, a price-to-earnings-growth ratio of 1.81 and a beta of 1.44. The firm's 50-day simple moving average is $84.31 and its 200 day simple moving average is $79.97. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the company posted $0.32 EPS. DexCom's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.